Litcius/Paper detail

Astrocytes Decreased the Sensitivity of Glioblastoma Cells to Temozolomide and Bay 11-7082

Sadaf E. Pustchi, Naze G. Avci, Yasemin M. Akay, Metin Akay

2020International Journal of Molecular Sciences28 citationsDOIOpen Access PDF

Abstract

Glioblastoma multiforme (GBM) is the most common malignant type of astrocytic tumors. GBM patients have a poor prognosis with a median survival of approximately 15 months despite the "Stupp" Regimen and high tumor recurrence due to the tumor resistance to chemotherapy. In this study, we co-cultured GBM cells with human astrocytes in three-dimensional (3D) poly(ethylene glycol) dimethyl acrylate (PEGDA) microwells to mimic the tumor microenvironment. We treated 3D co- and mono-cultured cells with Temozolomide (TMZ) and the nuclear factor-κB (NF-κB) inhibitor Bay 11-7082 and investigated the combined effect of the drugs. We assessed the expressions of glial fibrillary acidic protein (GFAP) and vimentin that play a role in the tumor malignancy and activation of the astrocytes as well as Notch-1 and survivin that play a role in GBM malignancy after the drug treatment to understand how astrocytes induced GBM drug response. Our results showed that in the co-culture, astrocytes increased GBM survival and resistance after combined drug treatment compared to mono-cultures. These data restated the importance of 3D cell culture to mimic the tumor microenvironment for drug screening.

Topics & Concepts

TemozolomideGlial fibrillary acidic proteinVimentinCancer researchTumor microenvironmentMedicineBrain tumorCell cultureAstrocyteMalignancyPathologyGliomaBiologyInternal medicineImmunohistochemistryTumor cellsCentral nervous systemGeneticsGlioma Diagnosis and TreatmentCancer Cells and MetastasisImmune cells in cancer
Astrocytes Decreased the Sensitivity of Glioblastoma Cells to Temozolomide and Bay 11-7082 | Litcius